The long-term objective of this study is to reveal the structure and function relationships of the nuclear receptor peroxisome proliferator-activated receptor ? (PPAR?), which regulates a wide range of human physiology including adipocyte differentiation, glucose homeostasis, and inflammatory responses. PPAR? ligands such as rosiglitazone (AvandiaTM) and pioglitazone (ActosTM) are currently used in the treatment of type 2 diabetes in humans. In monocytes/macrophages, PPAR? is able to reduce the levels of cytokines (TNFa, interleukin-?, and interleukin-6) by inhibiting the expression of these pro-inflammatory genes. This anti-inflammatory effect of PPAR? is highly associated with the treatment of atherosclerosis. Therefore, PPAR? is an attractive therapeutic target for the treatment of such cardiovascular diseases. While many synthetic ligands have been developed, the physiological ligands of PPAR? remain a matter of great debate. The recently identified endogenous PPAR? ligands like nitrolinoleic acid (LNO2) are abundant in vivo and may help elucidate the physiological relevance of PPAR? and NO signaling in cardiovascular diseases. As a nuclear receptor, PPAR? mediates its function through ligand binding to its C-terminal ligand-binding domain (LBD) and targeted gene promoter binding to its middle DNA-binding domain (DBD). PPAR? also contains a potent N- terminal activation domain, AF1. Until recently, structures were available only for the isolated PPAR? LBD bound to diverse synthetic ligands and to short peptide motifs of coactivators. Clearly, this limited amount of structural information is a serious deficiency considering the importance of PPAR? in diabetes and cardiovascular diseases. In this study, we propose to fill in this knowledge gap by solving the crystal structures of various PPAR? complexes.
Our specific aims are focused on the crystallization and structural determination of 1) the PPAR? LBD bound to LNO2, which will provide the first view of PPAR? bound to a natural ligand;2) the PPAR? LBD in complex with the PPAR? coactivator PGC1a;and 3) a PPAR? DBD-hinge-LBD fragment bound to RXR and a DNA of the PPAR response element (PPRE). The hypothesis for our specific aims is that the molecular interactions (protein-protein, protein-DNA, and protein-ligand) observed in those crystal structures will be crucial for understanding the biological functions of PPAR?. Following the structural determination, we will identify key structural elements by scrutinizing and analyzing the structures, and we will collaborate with Steve Kliewer (University of Texas Southwestern Medical Center), Eugene Chen (University of Michigan), and Bruce Freeman (University of Pittsburgh) on site-directed mutagenesis and cell-based transcriptional assays to validate the functional significance of the key features identified. Relevance: The structural information generated in this application will significantly enhance our understanding of the molecular mechanisms of PPAR? functions, and it should provide a rational template of drug discovery for the treatment of diabetes and heart diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL089301-03
Application #
7633197
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Srinivas, Pothur R
Project Start
2007-08-01
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$455,000
Indirect Cost
Name
Van Andel Research Institute
Department
Type
DUNS #
129273160
City
Grand Rapids
State
MI
Country
United States
Zip Code
49503
Gupta-Malhotra, Monesha; Hashmi, Syed Shahrukh; Poffenbarger, Tim et al. (2016) Left Ventricular Hypertrophy Phenotype in Childhood-Onset Essential Hypertension. J Clin Hypertens (Greenwich) 18:449-55
Cui, Shuaiying; Tanabe, Osamu; Lim, Kim-Chew et al. (2014) PGC-1 coactivator activity is required for murine erythropoiesis. Mol Cell Biol 34:1956-65
Gupta-Malhotra, Monesha; Kern, Jeffrey H; Flynn, Patrick A et al. (2013) Cardiac troponin I after cardiopulmonary bypass in infants in comparison with older children. Cardiol Young 23:431-5
Sahu, Raj; Pannu, Hariyadarshi; Yu, Robert et al. (2013) Systemic hypertension requiring treatment in the neonatal intensive care unit. J Pediatr 163:84-8
Zhi, Xiaoyong; Zhou, X Edward; Melcher, Karsten et al. (2012) Structural conservation of ligand binding reveals a bile acid-like signaling pathway in nematodes. J Biol Chem 287:4894-903
Malapaka, Raghu R V; Khoo, Sokkean; Zhang, Jifeng et al. (2012) Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem 287:183-95
Yu, Shanghai; Xu, H Eric (2012) Couple dynamics: PPAR? and its ligand partners. Structure 20:2-4
Agopian, A J; Moulik, Mousumi; Gupta-Malhotra, Monesha et al. (2012) Descriptive epidemiology of non-syndromic complete atrioventricular canal defects. Paediatr Perinat Epidemiol 26:515-24
Zhou, X Edward; Suino-Powell, Kelly M; Xu, Yong et al. (2011) The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor. J Biol Chem 286:2877-85
Zhou, X Edward; Suino-Powell, Kelly M; Li, Jun et al. (2010) Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J Biol Chem 285:9161-71

Showing the most recent 10 out of 23 publications